0.00Open1.96Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover0.00%IV-17.65%PremiumAug 16, 2024Expiry Date2.04Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.23Leverage Ratio--Theta--Rho--Eff Leverage--Vega
IGC Pharma Stock Discussion
Preclinical Analyses of Tgr-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed i...
Benzinga· 3 mins ago
Anson Funds agreed to a $2.25 million settlement with the Securities and Exchange Commission (SEC) over a secret relationship with a short seller affecting two cannabis companies. The SEC found that while Anson Funds disclosed its short position strategy to investors, it did not reveal its collaboratio...
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
Larger Image: tradingview.com...
$IGC Pharma(IGC.US)$
Get in on this
$IGC Pharma(IGC.US)$
No comment yet